Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats

Table 3

Changes in the plasma and hepatic lipids, atherogenic index (AI), and coronary artery index (CRI) in HFD-fed rats receiving 8-week treatment with myricetin or fenofibrate.

Variable (s)	RCD-fed	HFD-fed
	vehicle	Vehicle	Myricetin (mg kg^−1 per day)			Fenofibrate
			75	150	300	(100 mg kg^−1 per day)
Plasma TC (mg dL^−1)	71.4 ± 6.7^d	143.2 ± 11.9^b	128.4 ± 9.5^b	109.6 ± 7.7^a, c	98.3 ± 7.3^a, c	84.2 ± 8.0^d
Plasma TG (mg dL^−1)	55.7 ± 5.9^d	134.5 ± 5.7^b	116.4 ± 6.1^b	99.8±4.7^b, c	84.3±4.3^b, c	65.6±4.7^d
Plasma LDL-C (mg dL^−1)	31.2 ± 3.3^d	103.2 ± 3.9^b	84.9 ± 5.3^b,c	66.2±4.7^b,c	49.5±4.1^a, d	40.4 ± 4.3^d
Plasma HDL-C (mg dL^−1)	45.6 ± 3.1^d	26.4 ± 3.2^b	30.5 ± 3.5^b	37.1 ± 2.9^a, c	41.7 ± 3.1^d	43.6 ± 4.4^d
Plasma FFAs (mg dL^−1)	27.6 ± 2.7^d	63.8 ± 4.1^b	56.9 ± 4.3^b	48.5±3.8^b, c	38.7 ± 3.2^a, d	34.2 ± 3.5^d
Hepatic TC (mg g^−1)	2.6 ± 0.8^d	5.2 ± 0.7^b	4.6 ± 0.5^b	4.3 ± 0.4^a	3.4 ± 0.3^c	3.1 ± 0.5^c
Hepatic TG (mg g^−1)	9.0 ± 1.1^d	19.0 ± 1.2^b	17.8 ± 1.4^b	17.2 ± 1.1^a	12.5 ± 1.2^c	11.1 ± 0.8^c
AI	0.7 ± 0.2^d	3.9 ± 0.2^b	2.8 ± 0.1^b	1.8±0.3^a, c	1.2 ± 0.2^a, d	0.9 ± 0.3^d
CRI	1.6 ± 0.2^d	5.5 ± 0.6^b	4.2±0.5^b	2.9±0.4^a, c	2.2 ± 0.3^d	1.9 ± 0.4^d

Myricetin or fenofibrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2 mL kg⁻¹ once a day into HFD-fed rats. The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. ^a𝑃<.05 and ^b𝑃<.01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. ^c𝑃<.05 and ^d𝑃<.01 compared to the values of vehicle-treated HFD-fed rats in each group, respectively.